Open AccessComparison of Drug and Cell‐Based Delivery: Engineered Adult Mesenchymal Stem Cells Expressing Soluble Tumor Necrosis Factor Receptor II Prevent Arthritis in Mouse and Rat Animal Models
Author(s) -
Liu Linda N.,
Wang Gang,
Hendricks Kyle,
Lee Keunmyoung,
Bohnlein Ernst,
Junker Uwe,
Mosca Joseph D.
Publication year - 2013
Publication title -
stem cells translational medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.781
H-Index - 71
eISSN - 2157-6580
pISSN - 2157-6564
DOI - 10.5966/sctm.2012-0135
Subject(s) - tumor necrosis factor alpha , mesenchymal stem cell , etanercept , arthritis , cancer research , immunology , inflammation , medicine , stem cell , immune system , biology , microbiology and biotechnology , pathology
Human soluble tumor necrosis factor receptor II (hsTNFR) protein delivery from genetically engineered human mesenchymal stem cells (hMSCs) was compared with that of etanercept. Implanted hsTNFR‐transduced mesenchymal stem cells reduced mouse serum circulating tumor necrosis factor‐α (TNFα) generated from either implanted TNFα‐expressing cells or lipopolysaccharide induction more effectively than etanercept, suggesting faster clearance of the soluble tumor necrosis factor receptor‐TNFα complex from the animals. The data support the utility of hMSCs as therapeutic gene delivery vehicles and their potential to be used in alleviating inflammation within the arthritic joint.